Stay updated on Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.

Latest updates to the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedChangelog updated with Revision: v3.5.2 added and Revision: v3.5.0 removed.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor metadata update with no changes to study information.SummaryDifference0.1%

- Check54 days agoChange DetectedAdds explicit institution names (Moffitt Cancer Center and Research Institute) and a 'Helpful Links Provided by' section to the study page, clarifying sponsorship and related resources.SummaryDifference0.2%

- Check68 days agoChange DetectedDeleted footer elements include the Moffitt sponsor attribution and the Helpful Links section. This reduces visibility of institutional affiliation and access to related resources on the study page.SummaryDifference0.2%

- Check75 days agoChange DetectedRevision: v3.4.2 was added and the previous funding-status notice (Revision: v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.